Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Behavioural Neurology, Journal Year: 2023, Volume and Issue: 2023, P. 1 - 17

Published: Oct. 12, 2023

Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's which present major healthcare concerns on a worldwide scale. Despite lack available therapies, been shown to possess variety pharmacological effects preclinical clinical studies, making it an intriguing competitor. review brings together most recent findings endocannabinoid neurotransmitter systems, as well anti-inflammatory pathways, that underlie CBD's modes action. Synthesized efficacy safety assessments range illnesses are included, covering human trials, vitro animal models. The investigation includes how could protect neurons, control neuroinflammation, fend off oxidative stress, manage neuronal excitability. study emphasizes existing studies future possibilities research, addressing research issues such regulatory complications contradicting results, advocates further ideal dose methodologies. By emphasizing improve patient well-being, this presents revised viewpoint suitability intervention illnesses.

Language: Английский

---

Comorbidity of attention deficit hyperactivity disorder in a patient with epilepsy: Staring down the challenge of inattention versus nonconvulsive seizures

Epilepsy & Behavior Reports, Journal Year: 2024, Volume and Issue: 25, P. 100651 - 100651

Published: Jan. 1, 2024

Epilepsy is a heterogeneous disorder of recurrent seizures which often comorbid with anxiety, depression, attention deficit hyperactivity (ADHD), intellectual disability (ID), and other psychiatric manifestations. Treating both epilepsy behavioral symptoms from disorders can result in polypharmacy interactions medications leading to worsened efficacy antiseizure due psychotropic effects worsening medication side effects. We aim suggest pragmatic strategies for the neurologist diagnosis management ADHD patients based on International League Against (ILAE) Pediatric Commission guidelines additional literature review. The screening tool choice validated country practice written language family, though various tools advantages disadvantages each will be discussed. Once diagnosed, recent safety data that Methylphenidate, Amphetamine, Atomoxetine are generally safe epilepsy. present case child discuss clinical signs, symptoms, treatment as well when refer psychiatry.

Language: Английский

---

Análise da utilização da Cannabis sativa na prática da clínica veterinária de pequenos animais: uma visão atual

PubVet, Journal Year: 2025, Volume and Issue: 19(01), P. e1718 - e1718

Published: Jan. 7, 2025

In the current scenario, Cannabis sativa has been highlighted due to increasing use of its components in treatment various pathologies, both human and veterinary medicine. The present study aims identify ways which is used Veterinary Medical Clinics today. For this, a methodology for bibliographic review. Finally, data found was compared proven, where Clinic verified chronic atopic dermatitis, epilepsy, travel-induced stress urothelial cancer dogs, addition as analgesics osteoarthritis. cats.

Language: Английский

---

A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome

Cannabis and Cannabinoid Research, Journal Year: 2025, Volume and Issue: unknown

Published: March 14, 2025

Introduction: Medicinal cannabis (MC) has potential therapeutic effects in Tourette Syndrome (TS), however there been limited research adolescent patients. This pilot study aimed to investigate the feasibility of conducting a randomized placebo-controlled crossover trial MC adolescents with TS. Method: was phase I/II double-blind, cross-over comparing matched placebo aged 12-18 years The active medication Δ9-tetrahydrocannabinol (THC) 10 mg/mL and CBD 15 peppermint-flavored medium-chain triglyceride oil. dose titration schedule stratified into two participant weight bands: below 50 kg (max THC mg/day) or ≥50 20 mg/day). Each treatment lasted weeks, 4-week washout period. Results: Ten were (mean age 14.8 years, 50% male) seven completed full protocol. Two discontinued due adverse events (one on MC, one placebo) lost follow-up. most common event dizziness (67%). There no serious events. Among actively enrolled participants, protocol adherence excellent: visits 100%, blood test completions online questionnaire completion 97.6%. Medication acceptable 63.6%. Parents reported high degree design acceptability. On Clinical Global Impression-Improvement scale, three participants rated as much improved compared at weeks. Discussion: findings suggest that is feasible patients TS their families. A fully powered needed evaluate efficacy

Language: Английский

---

Characterizing the Population of a Medical Cannabis Clinic in a Pediatric Hospital

Journal of Palliative Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Background: Medical cannabis (MC) is increasingly in use due to recent cultural and political changes. Other than patients with Lennox-Gastaut Dravet syndrome, there inadequate literature provide evidence-based support for prescribing MC pediatric patients. Objectives: Characterize the population receiving an recommendation ambulatory palliative care setting quantify patient/family-reported outcomes. Design: Retrospective chart review of electronic medical record (EMR) data. Setting/Subjects: Total n = 46 consecutive advice regarding (n 42) a specialized clinic embedded division 4 inpatient midwestern U.S. hospital between 2019 2022. Measurements: Demographics, diagnosis, symptoms, adverse reactions, patient-reported outcomes, barriers abstracted from EMR. Results: Our sample included mean age 11.7 years (SD 5.4); 50% had neurological diagnosis 25); 37% 14) hematological/oncologic; 13% 6), chronic pain. The most common type recommended was 1:1 Cannabidiol (CBD): tetrahydrocannabinol (THC) tincture. There statistically significant decrease floor days cost. Totally, 35% were able or discontinue other medications. Thematic analysis identified four (product unavailable, difficulty obtaining state card, cost, organizational) subjective symptom improvement. Conclusions: These data characterize at our hospital. Positive outcomes noted across several domains. seems be associated lower health utilization, reduced polypharmacy, increased quality life used without events. In value-conscious environment, warrant further exploration.

Language: Английский

---

Medicinal Cannabis for Emotional and Behavioural Symptoms: Parent and Physician Perspectives

Journal of Paediatrics and Child Health, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Language: Английский

---

Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder

NeuroMolecular Medicine, Journal Year: 2024, Volume and Issue: 26(1)

Published: May 14, 2024

Abstract The salient features of autism spectrum disorder (ASD) encompass persistent difficulties in social communication, as well the presence restricted and repetitive facets behavior, hobbies, or pursuits, which are often accompanied with cognitive limitations. Over past few decades, a sizable number studies have been conducted to enhance our understanding pathophysiology ASD. Preclinical rat models proven be extremely valuable simulating analyzing roles wide range established environmental genetic factors. Recent research has also demonstrated significant involvement endocannabinoid system (ECS) pathogenesis several neuropsychiatric diseases, including In fact, ECS potential regulate multitude metabolic cellular pathways associated autism, immune system. Moreover, emerged promising target for intervention high predictive validity. Particularly noteworthy resent preclinical rodents, describe onset ASD-like symptoms after various pharmacological interventions targeting ECS, providing encouraging evidence further exploration this area.

Language: Английский

---

Effects of Medical Cannabis Treatment for Autistic Children on Anxiety and Restricted and Repetitive Behaviors and Interests: An Open-Label Study

Cannabis and Cannabinoid Research, Journal Year: 2024, Volume and Issue: unknown

Published: July 24, 2024

The literature supports the benefits of medical cannabis for core and comorbid symptoms in autistic individuals anxiety-related without autism. However, no study has specifically investigated how cannabidiol (CBD)-rich affects anxiety subtypes children or its relationship with restricted repetitive behaviors interests (RRBI). Understanding effects CBD-rich treatment on RRBI could offer more precise approaches to managing reducing frequency children.

Language: Английский

---

New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(12), P. 3567 - 3567

Published: June 18, 2024

Epilepsy is a disorder characterized by abnormal brain neuron activity, predisposing individuals to seizures. The International League Against (ILAE) categorizes epilepsy into the following groups: focal, generalized, generalized and unknown. Infants are most vulnerable pediatric group condition, with cause of development being attributed congenital developmental defects, white matter damage, intraventricular hemorrhage, perinatal hypoxic-ischemic injury, stroke, or genetic factors such as mutations in Sodium Channel Protein Type 1 Subunit Alpha (SCN1A) gene. Due risks associated this we have investigated how latest pharmacological treatments for children impact reduction complete elimination We reviewed literature from 2018 2024, focusing on age month 18 years old, some studies including well older individuals. significance review present compile research findings antiseizure drugs (ASDs), their effectiveness, dosing, adverse effects population, which can contribute selecting best drug particular patient. medications described shown significant efficacy safety studied patient group, outweighing observed effects. main aim provide comprehensive summary current state knowledge regarding newest pharmacotherapy childhood epilepsy.

Language: Английский

---

Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism

Developmental Neurobiology, Journal Year: 2024, Volume and Issue: 85(1)

Published: Nov. 27, 2024

ABSTRACT Autism spectrum disorder (ASD) is characterized by deficits in communication, social interaction, and repetitive stereotyped behaviors, with no specific drug therapy available. Studies have found that cannabidiol (CBD) can improve hyperactive cognitive symptoms children ASD. However, little known about the effect of CBD combination other medications, such as risperidone (RISP). This study aimed to evaluate behavioral biochemical effects animals using a valproic acid (VPA)‐induced ASD animal model. VPA was administered pregnant Wistar rats on Day 12.5 gestation induce From 10th 16th postnatal day (PND), neurodevelopment assessed through eye‐opening, olfactory discrimination, negative geotaxis tests. PNDs 9 54, were weighed. They treated for 21 days alone (100 mg/kg, gavage, twice day) or RISP (0.1 once day). At PND 55, evaluated interaction locomotor activity experiments. Finally, after assessment, euthanized, brain isolated, oxidative stress parameters hippocampus cortex posterior. Animals exposed showed neurodevelopmental delays opening their eyes, difficulties turning around axis, took longer time find original nest when compared control animals. also exhibited impaired sociability reduced exploratory activity, which indicates model impairments. Interestingly, + significantly improved parameters, whereas isolated did not affect this parameter. In analysis, significant decrease hippocampal sulfhydryl content noted CT group an increase group. conclusion, these results suggest CBD, RISP, may be interesting pharmacological approach reducing ASD‐related symptoms. Summary : Besides increased prevalence cases recent years, there are medications central autism. Numerous studies discuss important medication improving symptoms; however, it how interacts commonly used drugs individuals, RISP. demonstrated therapy, only combined VPA‐induced

Language: Английский

---